Summary The current work was undertaken to investigate the importance of exposure sequence and duration in achieving the maximum reversal action of S9788 on doxorubicin (DOX) cytotoxicity against cells that exhibit the (MDR) multidrug resistance phenotype: the MCF7/DOX cell line. Accumulation and release of DOX were examined in this cell line. The reversal effect was compared with that obtained with verapamil. S9788 activity was schedule dependent: when comparing incubation with S9788 before or after treatment with DOX, the best reversal factor was obtained in the case of a post-treatment incubation (65.6 ± 7.7 vs 20.8 ± 7.0). S9788 was a more potent modulating agent than verapamil, whatever the schedule of exposure of the cells to the reversal agent. The reversal of resistance after short-term DOX exposures was caused not only by prolonged cellular accumulation of DOX, but also by its prolonged retention after transfer of cells to DOX-free medium. A relationship was noted between cellular exposure to DOX and the cytotoxic effect, and so the reversal of resistance induced by S9788 appears to be directly linked to the level of cell exposure to DOX. This work provided a rationale for improving the schedule of administration of S9788 in clinical trials.
The development of resistance of human cancers to potent anti-cancer agents has been classically ascribed to the selection and outgrowth of a pre-existing or newly emerging subpopulation of resistant tumour cells (Coldman & Goldie, 1985 , Carl, 1989 . Great progress in the understanding of the mechanism of one type of in vitro-derived resistance, socalled multidrug resistance (MDR), was recently achieved by the successful cloning of the mdrl gene, which encodes a 170 kDa plasma membrane protein called P-glycoprotein (Pgp) (Gottesman & Pastan, 1988) .
A wide variety of compounds have now been shown to reverse MDR in vitro, including calcium channel antagonists (verapamil and analogues; Tsuruo et al., 1982 Tsuruo et al., , 1983 , calmodulin antagonists (trifluoperazines and analogues; Ganapathi & Grabowski, 1983; Akiyama et al., 1986) , steroids (progesterone), immunomodulators (cyclosporin A and analogues ; Twentyman, 1988) , antimalarial drugs (quinine, quinidine ; Tsuruo et al., 1984) , oestrogen receptor inhibitors (tamoxifen, toremifene; Ramu et al., 1984 , De Gregorio et al., 1989 , and others. Verapamil (Ozols et al., 1987; Pennock et al., 1991) , cyclosporin A (Yahanda et al., 1992) and quinine (Solary et al., 1992) have been used in early clinical trials, but results have been disappointing so far, one cause probably being the impossibility of sufficient dose escalation owing to the prohibitive toxicity of the reversal agent.
The search for novel and more potent modulators of the MDR phenotype that are not limited by side-effects is therefore of major importance. S9788 is a novel triazinoaminopiperidine derivative which has demonstrated potent reversal of the MDR phenotype in vitro and in vivo . It induces a dose-dependent increase in doxorubicin (DOX) accumulation. It is twice as active and approximately seven times more potent than verapamil Pierre et al., 1992) . In vivo, S9788 restored the anti-tumour activity of vincristine in a dosedependent manner in the P388/VCR leukaemia model (Cros et al., 1992) .
The current work was undertaken to investigate the importance of exposure sequence and duration in achieving the maximal reversal action of S9788 on DOX cytotoxicity against cells that exhibit the MDR phenotype: the MCF7/ DOX cell line. This reversal effect was compared with that of verapamil, which is considered to be the reference compound. The effects of various exposure schedules (simultaneous or sequential incubation) on clonogenic assay and on accumulation and release of DOX were examined in the MCF7/DOX cell line (900-fold resistant to DOX) compared with the sensitive cell line.
Materials and methods
Drugs Doxorubicin (DOX) was obtained from Farmitalia Carlo Erba (Rueil-Malmaison, France) and was dissolved in sterile water to a final concentration of 2 mg ml-'. The clinical formulation of verapamil (VRP, Isoptine) was purchased from Biosedra (Malakoff, France). S9788 (6-4-[2,2-di(4-fluorophenyl)ethylamino]piperidinl-yl N,N'-dipropen-2-yl 1,3,5-triazine 2,4-diamine, bismethanesulphonate) was synthesised at the Servier Research Institute (Courbevoie, France (Lucas et al., 1993) or VRP (Ozols et al., 1987; Cairo et al., 1989 (10, 20, 30 and 60 min) . Cells were washed twice in ice-cold phosphate-buffered saline (PBS), trypsinised, and the cell-associated drug concentrations were determined by high-performance liquid chromatography (HPLC) with fluorimetric detection after sonication and extraction by organic solvent as described elsewhere (Muller et al., 1993 washed, trypsinised and counted as previously described. Efflux at each time point was determined by the method described in the section on DOX accumulation.
Three independent experiments were performed in triplicate.
Results
Effect of S9788 on circumvention of multidrug resistance in MCF7/DOX cell line The results obtained with the new MDR modulator using different protocols on sensitive and resistant MCF7 cell lines are summarised in Table I . In the parental MCF7 cell line, S9788 had no effect on DOX cytotoxicity: the Sen. F was almost constant at about 1.
When MCF7/DOX cells were incubated simultaneously with DOX and S9788 for 1 h, Rev. F was low (7.3). This factor increased (Rev. F = 20.8) after an S9788 preincubation of 24 h. It reached 65.6 when S9788 was present during and 24 h after the exposure to DOX. Finally, the greatest effect of S9788 was obtained when a preincubation and a postincubation of 24 h were carried out (Rev. F = 105). However, the circumvention of resistance was still incomplete in the MCF7/DOX subline, the residual resistance factor being 10.7.
Pre-and post-incubation of 6 h before and after DOX incubation led to reversal factors of 19.4 and 39.8 respectively (protocols 6 and 4) ( Table I) .
When considering exposure of cells to S9788 by the product concentration x time, it is noteworthy that, for an equal exposure, the presence of S9788 in the culture medium during and after the end of incubation with DOX was more effective than its presence before incubation with DOX ( Figure 1 ).
Comparison with verapamil
The effects of S9788 and VRP on DOX cytotoxicity are compared in Figure 2 in (Figure 4) . Finally, the cytotoxic activity of DOX was related to 'effective drug exposure', which was defined as the area under the curve of plots of cell-associated DOX versus time. Figure  5 illustrates the effects of DOX cell exposure on the ICs of MCF7/DOX cells according to the different schedules tested. A logarithmic relationship was estbalished between these two parameters (r = 0.97): S9788 increases effective drug exposures to DOX, and this increase is related to the cytotoxic effect of this drug.
Discussion
In this work, we have examined and compared the effects of different schedules of exposure to two MDR reversal agents, VRP and S9788, on the cytotoxicity of DOX on an MDR cell line. Since the demonstration by Tsuruo et al. (1981) of a reversal of the MDR phenotype in P388 leukaemia by incubation with VRP and DOX, there have been numerous reports of synergism between these two drugs. In order to mimic clinical situations in which DOX is currently administered by i.v. bolus, in our study cells were exposed to this drug for 1 h. The study of Cairo et al. (1989) has pointed out the importance of a careful consideration of the peak plasma level and the pharmacokinetics of drugs to be used in reversal of multidrug resistance. In the case of S9788, the early pharmacokinetic data obtained during phase I clinical trials (Khayat et al., 1993; Lucas et al., 1993) optimum schedule for modulating MDR consisted in a 24 h pre-and post-incubation with 1 gM S9788 and concomitant exposure to S9788 and DOX. However, this regimen has not been used in the first clinical trials (Khayat et al., 1993) . We have also shown that, for an equal concentration x time exposure, S9788 activity is schedule dependent: the postincubation was more important for the activity (when comparing a pre with a post DOX incubation with S9788, the reversal factor was higher in the case of a post-incubation). Similar results have been obtained with VRP (Cass et al., 1989; Toffoli et al., 1993) . Moreover, the results presented here show that there is no direct relationship between increasing post-incubation exposure to S9788 and reversal of MDR resistance: an exposure of 24 h to 1 JAM S9788 (corresponding to a C x T= 25 JLM x h) led to a reversal factor of 65 ± 7, whereas an exposure of 6 h (C x T = 7 JiM x h) produced a Rev. F of 40 ± 7. This C x T of 7 JM x h could be of clinical relevance, since the human pharmacokinetic data showed that such an AUC could be reached in clinical trials combining a loading dose and a continuous infusion of S9788 following cytotoxic drug administration. All these results might be due to the cellular pharmacokinetics of S9788: Perez et al. (1993) after the cells are washed the retention of S9788 is about 20% of the initial concentration. Our study confirmed that S9788 is a more potent modulating agent than VRP, whatever the schedule of exposure of the cells to the reversal agent. Compared with VRP, the superior effect of S9788 may be explained, in part, by its higher affinity for Pgp, as suggested by its greater ability to inhibit [3H]azidopidine photolabelling and in part by the difference in cellular pharmacokinetics of these drugs: for equal extracellular concentrations (5 JM), S9788 was accumulated and retained by cells to a greater extent than VRP (Perez et al., 1993) . However, even when using the optimum schedule, reversal of resistance was incomplete in the MCF7/DOX cell line: residual resistance factors of 10 and 12.5 were observed for S9788 and VRP respectively. One explanation is the fact that the MCF7/DOX cell line expresses a very high degree of MDR and exhibits several mechanisms of resistance including mdrl gene overexpression, increased antioxidant defence system and topoisomerase I and II modifications (Batist et al., 1986) . On the other hand, it has been established that the activity of S9788 depends on both the MDR cell line used (i.e. the Pgp level or the resistance factor) and the method of selection of resistance . The method of selection of resistance seems to be very important since the reversal of resistance to DOX in all cell lines obtained by selection on DOX was incomplete. By contrast, a human mdrl-transfected cell line showed complete reversal by S9788 on vincristine resistance, confirming the mechanism of action of the compound .
Co-administration of MDR modulators with the various anti-cancer drugs associated with the MDR phenotype often results in increased net accumulation of drug in MDR cell lines (Luk & Tannock, 1989; Bruno & Slate, 1990; Huet et al., 1993) . In the MCF7/DOX cell line, we showed that the cellular content of DOX increased when S9788 and DOX were co-administered over a 1 h period. In addition, the loss of DOX from cells was reduced when S9788 was present during the release phase. Thus, the reversal of resistance after short-term DOX. exposures was the result not only of enhanced cellulag accumulation of DOX during DOX exposure, but also of enhanced retention after transfer of cells to DOX-free medium. These results confirmed that the maximum efficacy of S9788 can be achieved by administration of S9788 both during and after administration of the cytotoxic agent. Similar results have been found for VRP (Cass et al., 1989) . Moreover, the levels of intracellular DOX have been shown to correlate with cell survival (Keizer et al., 1989; Luk & Tannock, 1989) , and our results are in agreement with these data since a relationship was noted between cell exposure to DOX and its cytotoxic effect; thus, the reversal of resistance itself appears to depend directly on the level of accumulation of DOX (Ganapathi et al., 1984; Schuurhuis et al., 1989) . Other authors have shown (Huet et al., 1993 ) that DOX accumulation alone may not predict drug sensitivity; it may be necessary to consider subcellular drug distribution. Since the DOX accumulation measured by HPLC or by flow cytometry is a global detection, it is difficult to identify the various intracellular compartments containing DOX or, more precisely, the DOX molecules involved in the cytotoxicity. Different reports studying the intracellular distribution of DOX have shown that in parental cells fluorescence is predominantly nuclear, whereas in resistant cells fluorescence is distributed in the cytoplasm in distinct punctate regions (Keizer et al., 1989; Schuurhuis et al., 1989; Gervasoni et al., 1991 of fluorescence of DOX in MDR lines, particularly in the nucleus (Barrand et al., 1993; Coley et al., 1993) . Such a technique might be applied to S9788 to confirm the hypothesis expressed by Huet et al. (1993) that this drug could be able to decrease the intracellular IC50 independently of its efficiency in restoring DOX accumulation, thus reversing intracellular drug tolerance. Such a drug might be able to segregate DOX in subcellular compartments from which it could not reach its nuclear targets.
In conclusion, we have compared the efficacy of various schedules of administration of S9788 in combination with DOX in an MCF7/DOX cell line. The optimum resistance reversion was obtained when cells were incubated with S9788 before, during and after DOX exposure. However, to be compatible with clinical situations, a-post-incubation of at least 6 h with the modulator is recommended. The modulation efficiency of this MDR reversal agent was correlated with the DOX cellular content versus time.
